Poster Presentation 2025 Joint Meeting of the COSA ASM and IPOS Congress

MyeEx-Impact: a randomised controlled trial of bone-targeted exercise for people with multiple myeloma – an overview of study performance (126653)

Jennifer L Nicol 1 2 , Jamie E Chong 1 , Belinda Beck 3 , Shelley Kay 4 , Michelle McDonald 5 6 , Daniel Carter 1 , Hayley Beer 7 , Carmel Woodrow 8 , Brent C Cunningham 1 9 , Alex Boytar 10 , Brenton Baguley 11 , Peter Mollee 8 12 , Nicolas Hart 2 , Tina L Skinner 1 2 9 13
  1. School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia
  2. Human Performance Research Centre, INSIGHT Research Institute, University of Technology Sydney, Sydney, New South Wales, Australia
  3. Griffith University, Gold Coast, Queensland, Australia
  4. Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
  5. University of Sydney, Sydney, New South Wales, Australia
  6. Garvan Institute of Medical Research, Sydney, New South Wales, Australia
  7. Myeloma Australia, Melbourne, Victoria, Australia
  8. Haematology, Division of Cancer, Princess Alexandra Hospital, Brisbane, Queensland, Australia
  9. School of Health, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
  10. University of Toronto, Toronto, Ontario, Canada
  11. Deakin University, Geelong, Victoria, Australia
  12. UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
  13. School of Health Sciences, University of New South Wales, Sydney, New South Wales, Australia

Objective: 

Preclinical models using osteogenic exercise have demonstrated mechanical load-induced changes delay osteolytic activity and rescue bone loss. The MyeEx-Impact multi-site randomised controlled trial aims to examine whether bone-targeted exercise can improve bone health in people with multiple myeloma (MM). 

Sample and setting: 

People with MM (n=78) at trial sites in Brisbane (QLD) and Sydney (NSW).

Procedures:

After completion of baseline testing, participants will be randomised to exercise (EX) or control (CON). The EX group performs two supervised and one unsupervised sessions of individualised bone-targeted exercise each week over 9 months. The CON group receives usual care and maintains current activity levels. Primary (bone density and microarchitecture) and secondary (bone pain, quality of life, fatigue, physical function, sleep, psychological constructs, gut microbiome, disease response, biomarkers of bone health, immune function, and disease progression) outcomes are assessed at baseline, 3-, and 9-months. Adverse events, and adherence to the exercise program are monitored.

Results: 

The QLD site opened for recruitment in late 2024 and has screened 54 people with MM. Five people were deemed ineligible, with 15 people declining to participate. The NSW site is opening for recruitment imminently, with a waitlist of potential participants. To date, 27 people have consented, of whom 25 have completed baseline testing (two withdrew prior to completion). Eighteen participants have completed their 3-month testing, with four completing their 9-month testing. Ten people are randomised to exercise to date, with adherence of 81% and 75% to the resistance exercise and impact loading thus far. There have been seven low-grade (grade 1 and 2) adverse events reported. 

Conclusion: 

MyeEx-Impact is on track to reach its a priori recruitment target. Participants have had high adherence to resistance exercise and impact loading with few exercise-related adverse events, all of low grade, reported. The NSW site will be opening imminently.